Alaunos Therapeutics Inc. stocks have been trading up by 19.14 percent on renewed optimism surrounding its oncology pipeline.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Alaunos Therapeutics completed the Velaris Therapeutics acquisition, adding ActRII-Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
- In the Velaris deal, the company raised about $350M in a private placement expected to fund operations into 2029 and advance multiple drug candidates.
- Management plans to use new capital to push VLR199 for pulmonary arterial hypertension through key proof-of-concept milestones.
- Following the acquisition and funding news, shares of TCRT spiked roughly 126% in one account.
- Another report tied the same $350M Series C preferred private placement to a ~225% surge in TCRT on extremely heavy trading volume.
Live Update At 08:32:15 EDT: On Wednesday, October 14, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 19.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TCRT just morphed from a quiet micro-cap into a full-on momentum story. The daily chart tells the tale. On 2026/10/12, TCRT closed at $1.05. On 2026/10/13, it opened at $1.73, ripped to $4.32, dipped to $1.51, and closed at $3.03. That is a monster range for any biotech, and it reflects traders scrambling to reprice Alaunos Therapeutics after the Velaris news.
Zoom into the 5‑minute data and you see classic breakout behavior. Pre-market, TCRT pushed from the low $3s into the high $3s and low $4s, with repeated tests of the $4 area between 04:00 and 07:20. The stock then churned between $3.6 and $3.9, showing that day traders were actively scalping the tape rather than walking away.
More Breaking News
- DPZ Stock Under Pressure As Analysts Cut Long-Term Targets
- FFAI Stock In Focus As Robotics Pivot Accelerates
- CoreWeave Stock Slides As CRWV Unveils Dual Capital Raise
- VSTM Stock Draws Bulls As Oncology Data And Targets Rise
Under the hood, though, Alaunos Therapeutics is still a high-risk story. Revenue is tiny at roughly $5,000, with a pretax profit margin deeply negative. Operating cash flow for the latest quarter ran about -$300,000, free cash flow matched that, and the company ended the period with only $124,000 in cash before this new raise. TCRT showed a current ratio of 0.8 and working capital of -$198,000 — clear signs it needed fresh capital. The $350M private placement now changes that runway math in a big way, even though the core business remains pre-commercial and highly speculative.
Why Traders Are Watching TCRT Now
TCRT went from forgotten ticker to front-page scan material overnight because of one thing: narrative shift backed by serious capital. Alaunos Therapeutics closed its acquisition of Velaris Therapeutics and, with it, grabbed a pipeline of ActRII-Fc ligand traps and biologics aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. For a tiny biotech with almost no revenue, that kind of pipeline story is what fuels momentum trading.
The real spark, though, is the $350M private placement tied to this deal. Before the raise, Alaunos Therapeutics was operating with just over $124,000 in cash and negative working capital. Now, TCRT is signaling a cash runway into 2029. That removes the near-term funding overhang that usually hangs over names like this and gives management room to push VLR199 and other candidates through proof-of-concept and initial regulatory filings.
The market reaction shows how powerful that combo can be. One report pegs the TCRT surge at about 126%; another notes a roughly 225% spike on extremely heavy volume, all off the same Velaris and Series C preferred news. Exact percentage aside, traders saw a low-float biotech with new capital, a fresh clinical story, and a clear catalyst path. That is the recipe momentum traders scan for every day.
Intraday, Alaunos Therapeutics showed the textbook volatility profile: big gap up, wide ranges, repeated tests of key levels, and enough volume to get in and out quickly. For short-term traders, TCRT is now a live-wire ticker where both breakouts and brutal pullbacks are on the table. The extended runway and pipeline story give a strong narrative; the horrible legacy profitability and micro-cap scale make it fragile. That tension is exactly why TCRT is on so many watchlists.
Conclusion
For active traders, TCRT is a lesson in how fast a biotech narrative can flip when capital and catalysts line up. Alaunos Therapeutics was sitting on minimal revenue, steep losses, and a thin balance sheet as of 2026/06/30. In a single strategic swing — the Velaris Therapeutics acquisition plus a $350M private placement of Series C non-voting convertible preferred stock — the company secured a multi-year cash runway and a fresh pipeline aimed at pulmonary arterial hypertension.
That is why Alaunos Therapeutics exploded more than 100%–200% on massive volume after the news. The market is no longer trading TCRT as a cash-starved micro-cap; it is trading a high-volatility development story with enough capital to chase value-creating data. But the fundamentals still show no real revenue base and heavily negative returns on equity and assets. If any clinical or financing narrative cracks, the same leverage that pushed TCRT up can slam it down.
For traders studying this move, the key is discipline. Big percentage spikes like TCRT’s are gifts only if you manage risk. As Tim Sykes loves to remind his students, “Cut losses quickly, because big losses destroy both your account and your confidence.” That idea aligns closely with another core trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” Alaunos Therapeutics now sits at the crossroads of huge potential and huge risk. Use TCRT as a trading lesson, not a prediction — plan your levels, respect the volatility, and remember this is for education and research, not advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.